News
Pharmacy & healthcare news
Industry updates, regulation, and developments that matter to Indian pharmacies.
Govt panel recommends OTC sale Of Paracetamol, Ibuprofen, Levocetirizine across general stores
In a significant change that has the potential to redefine access to prevalent drugs, a government-nominated panel has suggested permiting over-the-counter (OTC) sale of 27 prescription medicines—like paracetamol, ibuprofen, and levocetirizine—through pharmacies and general stores alike.
Apr 24, 2025
Gujarat FDCA uncovers interstate counterfeit drug network using fake QR codes
In its first-ever milestone operation, Gujarat Food and Drug Control Administration (FDCA) has revealed a well-structured interstate network for counterfeit drugs spread across Maharashtra, Madhya Pradesh, Delhi, and West Bengal using spurious QR codes. T
Apr 24, 2025
Indian diabetics express concern over changes in human mixtard insulin therapy
As Novo Nordisk withdraws its Human Mixtard insulin, India's diabetic population—already the largest in the world—is caught up in anxiety and confusion.
Apr 24, 2025
Telangana DCA busts illegal network involved in sale of codeine-based cough syrups
Telangana Drug Control Administration (DCA), in coordination with the Prohibition and Excise wing of Ranga Reddy district, busted an illicit network involved in diversion and illegal sale of codeine-based cough syrups.
Apr 24, 2025
DavaIndia launches E-pharmacy platform in pune with 60-min delivery, regional language support
Davaindia, a leading private generic pharmacy retail chain, has expanded its digital footprint with the launch of its e-commerce platform in Pune.
Apr 23, 2025
Expert panel recommends ban on Ranitidine over cancer risk concerns
An expert panel has recommended a nationwide suspension on the manufacture, sale, and distribution of the popular antacid ranitidine in India, citing potential cancer risks due to high levels of NDMA impurities.
Apr 23, 2025
ICMR advises ban on Nimesulide doses above 100 mg, recommends black box warning
The Indian Council of Medical Research (ICMR) has suggested banning all Nimesulide preparations above 100 mg for adults and called for the imposition of a black box warning on all products with the drug on a mandatory basis.
Apr 23, 2025
Fujifilm India launches ELUXEO 8000 Endoscopy system to boost therapeutic precision
Fujifilm India has inaugurally launched its ELUXEO 8000 Therapeutic Endoscopy Solution at the 22nd MUMBAI LIVE Endoscopy event in India, hitherto solely available in Japan and Europe.
Apr 22, 2025
Hyderabad youth dies due to painkiller abuse, two arrested for selling illegally
In a shocking case, Hyderabad police arrested two people for their role in the death of a 17-year-old youth who died of complications after administering a potent painkiller, CP-DOL-100, reportedly sold over-the-counter.
Apr 22, 2025
IIT-BHU develops advanced drug detection sensor with real-time accuracy
Researchers at the School of Biochemical Engineering of the Indian Institute of Technology (IIT) BHU have developed an advanced electrochemical sensing device that can identify ultra-trace levels of drugs in pharmaceutical products and milk samples.
Apr 22, 2025
PhonePe’s PINCODE app launches 24×7 medicine delivery with 10-minute fulfilment in 3 cities
PhonePe's hyperlocal e-commerce platform, PINCODE app, has launched 24×7 medicine delivery service across Bangalore, Mumbai, and Pune, with deliveries within 10 minutes directly from local medical stores.
Apr 21, 2025
Telangana DCA conducts 65 seizures in March for drug offences
Telangana Drugs Control Administration (DCA) executed 65 seizures during March 2025 against offenses as varied as deceptive drug promotional campaigns to fake and expired drugs sale.
Apr 21, 2025
US FDA approves Medtronic's Simplera Sync sensor for MiniMed 780G system
The US Food and Drug Administration (FDA) has approved Medtronic’s Simplera Sync sensor for use with its MiniMed 780G insulin delivery system, marking a significant leap in automated diabetes management.
Apr 21, 2025
India's QR code packaging mandate aims to combat counterfeit medicines
India's bold mandate to implement QR codes on drug packaging has been hailed as a revolutionary move to combat counterfeit medicines.
Apr 20, 2025
AiMED opposes Gujarat’s pricing policy favouring USFDA-approved stents, seeks rollback
The Gujarat government's revised pricing model for drug-eluting stents (DES) under its public insurance scheme has triggered sharp criticism from domestic device manufacturers.
Apr 2, 2025
Glenmark pharma to launch generic adderall in five strengths by May 2025
Glenmark Pharmaceuticals Inc., USA has made a statement regarding its imminent launch of a generic form of the widely used ADHD medication Adderall in the US market.
Apr 19, 2025
Barnala clinic sealed for selling spurious ayurvedic medicines, case filed against operator
A clinic located in Raissar village in Barnala in Punjab has been sealed by the health department as it allegedly sold spurious Ayurvedic medicines.
Apr 18, 2025
Govt May Allow Common Medicines to Be Sold in General Stores Under New Policy
In a significant move, the Indian government is considering making common over-the-counter (OTC) medicines available in general stores....
Apr 18, 2024
Health ministry restricts use of common cold drug in children below 4 years
In a major step towards pediatric drug safety, the Union Health Ministry has limited the use of the popular common cold medication combination — Chlorpheniramine Maleate and Phenylephrine Hydrochloride — in children under four years of age.
Apr 17, 2025
Biocon Settles Biosimilar Dispute With Regeneron, To Launch Eye Disease Drug In US By 2026
Biocon Biologics, the biosimilars arm of Indian pharma giant Biocon, has settled a key patent litigation with US-based Regeneron Pharmaceuticals, clearing the way for the launch of its biosimilar aflibercept — Yesafili — in the United States market by the second half of 2026, or earlier under certain conditions. Key Highlights Settlement Finalized in US Court Biocon and Regeneron signed a settlement and licensing agreement to resolve litigation related to Yesafili, a biosimilar of Eylea, Regeneron’s blockbuster therapy for eye diseases. The pending appeal before the US Court of Appeals for the Federal Circuit and the litigation at the US District Court (West Virginia) will now be dismissed. Yesafili To Enter US Market by H2 2026 Under the settlement, Biocon is licensed to commercialize Yesafili in the US in H2 2026, or earlier in specific circumstances. Biocon becomes the first to-file interchangeable biosimilar of Eylea, marking its entry into the US ophthalmology market. Canada Launch Timeline Also Finalized Biocon has also settled with Bayer and Regeneron in Canada, allowing it to launch Yesafili no later than July 1, 2025. About Yesafili & Market Potential Yesafili is a VEGF inhibitor used to treat eye conditions such as age-related macular degeneration and diabetic retinopathy. It is a biosimilar of Eylea, which posted $5.97 billion in global revenue in 2024 according to Regeneron. The product is expected to expand Biocon’s biosimilars footprint in the lucrative US ophthalmology segment. Statements from Leadership Shreehas Tambe, CEO & MD of Biocon Biologics, said: “This settlement clears the path for Biocon Biologics and as the first to-file interchangeable biosimilar to Eylea, it marks our strategic entry into Ophthalmology, expanding our footprint in the U.S.” The Biocon-Regeneron settlement reflects Biocon’s aggressive global biosimilar strategy, particularly in high-value segments like ophthalmology. With patent disputes resolved and launch timelines fixed, Yesafili’s US and Canada entry will not only boost Biocon’s international revenue but also offer a cost-effective alternative in the eye care market. The next key watch will be commercial rollout plans and regulatory developments leading up to the 2026 launch.
Apr 16, 2025
CDSCO Directs States and UTs to Act Against 35 Unapproved FDCs
The Drugs Controller General of India (DCGI) has instructed State and Union Territory (UT) drug controllers to move against 35 fixed dose combinations (FDCs) that were recognized as unapproved new drugs.
Apr 16, 2025
Edwards SAPIEN M3 Mitral Valve Replacement System Gets CE Mark for Transcatheter Treatment
Edwards Lifesciences Corporation has received CE Mark approval for its SAPIEN M3 mitral valve replacement system, marking a significant advancement in treating patients with moderate-to-severe or severe mitral regurgitation (MR) who are not suitable for surgery or transcatheter edge-to-edge repair (TEER).
Apr 16, 2025
Customs Arrests Three in Indore for Illegal Alprazolam Supply
As part of a major drive against the illicit supply of controlled drugs, the Customs Department in Indore arrested three people associated with the illicit supply of more than 46,000 Alprazolam tablets.
Apr 15, 2025
DCA Delhi Seizes Counterfeit Thrombophob Ointment Worth ₹2.5 Lakh in Surprise Raid
In a major operation against spurious drugs, the Drugs Control Administration (DCA) Delhi has confiscated more than 1,400 spurious tubes of Thrombophob 20gm ointment from a whole seller in Bhagirath Place.
Apr 15, 2025
Ready to simplify your pharmacy?
Start your free 7-day trial or book a personalised demo today.